Allogeneic transplantation for multiple myeloma

Published: June 8, 2009
Abstract Views: 184
PDF: 188
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

In multiple myeloma (MM), the standard of treatment for patients < 65 years is high-dose chemotherapy followed by autologous stem cell transplantation. However, following either a single or a tandem autograft MM invariably recurs due to the persistence of tumor cells either in the host and/or in the graft. Purification procedures have generally proved unsuccessful. Allogeneic transplantation not only skips graft tumor contamination, but also exerts an immune effect against the myeloma clone. This effect is also displayed by donor lymphocytes when infused to the recipient in adeguate amounts. Despite these biological advantages, the precinse role of allograft in MM remains controversial.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Majolino, I., Carnevall, E., Locasciulli, A., Di Bartolomeo, P., Scimè, R., Corradini, P., Selleri, C., & Selleri, F. (2009). Allogeneic transplantation for multiple myeloma. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.428